Adaptive Dx

Adaptive Biotechnologies has commercialized next-generation sequencing-based diagnostic tests such as clonoSEQ®, the first and only FDA-cleared IVD test for minimal residual disease detection in multiple hematologic malignancies. The company also offers immune-sequencing platforms for research and clinical development, with a focus on leveraging the adaptive immune system's genetic information to diagnose, monitor, and potentially treat cancer, autoimmune diseases, and infectious diseases. Recent clinical results include expanded Medicare coverage of clonoSEQ® for mantle cell lymphoma recurrence monitoring and new partnerships to broaden access to their MRD testing.